Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer

Cancer Invest. 2014 May;32(4):150-7. doi: 10.3109/07357907.2014.889706. Epub 2014 Mar 7.

Abstract

Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients.

Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage.

Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin.

Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.

Trial registration: ClinicalTrials.gov NCT00930579.

Publication types

  • Controlled Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Biomarkers, Tumor / blood
  • Body Mass Index
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery
  • Cell Proliferation / drug effects*
  • Chemotherapy, Adjuvant
  • Cholesterol / blood
  • Drug Administration Schedule
  • Female
  • Humans
  • Leptin / blood
  • Metformin / administration & dosage*
  • Middle Aged
  • Neoplasm Staging
  • New York City
  • Obesity / blood
  • Obesity / diagnosis
  • Obesity / drug therapy*
  • Overweight / blood
  • Overweight / diagnosis
  • Overweight / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Leptin
  • Metformin
  • Cholesterol

Associated data

  • ClinicalTrials.gov/NCT00930579